Mapping Local Failure Following Bladder Radiotherapy According to Dose.

Cross-Sectional Studies Humans Neoplasm Recurrence, Local / diagnostic imaging Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted / methods Radiotherapy, Intensity-Modulated / adverse effects Urinary Bladder / diagnostic imaging Urinary Bladder Neoplasms / diagnostic imaging
Bladder cancer radiotherapy IMRT deformable registration patterns of local failure

Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
10 2022
Historique:
received: 25 02 2022
revised: 06 04 2022
accepted: 05 05 2022
pubmed: 13 6 2022
medline: 21 9 2022
entrez: 12 6 2022
Statut: ppublish

Résumé

To determine the relationship between local relapse following radical radiotherapy for muscle-invasive bladder cancer (MIBC) and radiation dose. Patients with T2-4N0-3M0 MIBC were recruited to a phase II study assessing the feasibility of intensity-modulated radiotherapy to the bladder and pelvic lymph nodes. Patients were planned to receive 64 Gy/32 fractions to the bladder tumour, 60 Gy/32 fractions to the involved pelvic nodes and 52 Gy/32 fractions to the uninvolved bladder and pelvic nodes. Pre-treatment set-up was informed by cone-beam CT. For patients who experienced local relapse, cystoscopy and imaging (CT/MRI) was used to reconstruct the relapse gross tumour volume (GTV Between June 2009 and November 2012, 38 patients were recruited. Following treatment, 18/38 (47%) patients experienced local relapse within the bladder. The median time to local relapse was 9.0 months (95% confidence interval 6.3-11.7). Seventeen of 18 patients were evaluable based on the availability of cross-sectional relapse imaging. A significant difference between DIR and RIR methods was seen. With the DIR approach, the median GTV Relapse following radiotherapy occurred within close proximity to the original bladder tumour volume and within the planned high-dose region, suggesting possible biological causes for failure. We advise caution when considering margin reduction for future reduced high-dose radiation volume or partial bladder radiotherapy protocols.

Identifiants

DOI: 10.1016/j.clon.2022.05.003 PMID: 35691760 PMC: PMC9515812
pubmed: 35691760
pii: S0936-6555(22)00224-2
doi: 10.1016/j.clon.2022.05.003
pmc: PMC9515812
pii:
doi:

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e421-e429

Subventions

Organisme : Department of Health
ID : ICA-SCL-2018-04-ST2-002
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C33589/A19727
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C33589/A28284
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Clin Oncol (R Coll Radiol). 2021 Jun;33(6):350-368
pubmed: 33972024
BMC Med. 2013 Apr 10;11:104
pubmed: 23574966
Radiology. 2018 Feb;286(2):502-511
pubmed: 29206594
Clin Oncol (R Coll Radiol). 2012 Dec;24(10):673-81
pubmed: 22858439
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):705-12
pubmed: 20472358
Radiat Oncol. 2017 Aug 15;12(1):129
pubmed: 28806994
Clin Oncol (R Coll Radiol). 2020 Feb;32(2):93-100
pubmed: 31400946
Radiat Oncol. 2016 Jul 26;11(1):95
pubmed: 27460585
Adv Radiat Oncol. 2020 May 15;5(5):929-935
pubmed: 33083655
Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):738-741
pubmed: 33421558
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):197-207
pubmed: 15093917
Clin Oncol (R Coll Radiol). 2021 Jun;33(6):407-414
pubmed: 33726945
Strahlenther Onkol. 2012 Aug;188(8):671-6
pubmed: 22580623
J Clin Oncol. 2017 Jul 10;35(20):2299-2305
pubmed: 28410011
Radiother Oncol. 2018 Jan;126(1):139-147
pubmed: 29050960
Med Phys. 2015 Jan;42(1):40-53
pubmed: 25563246
J Urol. 2000 Jun;163(6):1693-6
pubmed: 10799162
Radiology. 2015 Mar;274(3):752-63
pubmed: 25380454
Clin Transl Radiat Oncol. 2020 Sep 11;25:46-51
pubmed: 33015380
Clin Oncol (R Coll Radiol). 2019 Sep;31(9):646-652
pubmed: 31301959
Oncotarget. 2018 Apr 17;9(29):20439-20450
pubmed: 29755663
BMJ Open. 2020 Dec 31;10(12):e041005
pubmed: 33384390
Clin Oncol (R Coll Radiol). 2021 Jun;33(6):e251-e256
pubmed: 33766502
Clin Oncol (R Coll Radiol). 2020 Dec;32(12):805-816
pubmed: 33071029
Urology. 2001 Sep;58(3):380-5
pubmed: 11549485
Crit Rev Oncol Hematol. 2015 Apr;94(1):105-15
pubmed: 25541350
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1022-30
pubmed: 27026308
Clin Oncol (R Coll Radiol). 2017 Jun;29(6):344-347
pubmed: 28190637
J Clin Oncol. 2014 Dec 1;32(34):3801-9
pubmed: 25366678
Clin Oncol (R Coll Radiol). 2014 Aug;26(8):497-505
pubmed: 24726459
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):261-9
pubmed: 23958147
Radiat Oncol. 2012 Jul 23;7:111
pubmed: 22824133
J Clin Oncol. 2010 Nov 20;28(33):4912-8
pubmed: 20956620
Front Oncol. 2021 Feb 25;11:637591
pubmed: 33718230
N Engl J Med. 2012 Apr 19;366(16):1477-88
pubmed: 22512481
Eur J Radiol. 2017 Oct;95:46-55
pubmed: 28987698
Eur Urol. 2018 Sep;74(3):294-306
pubmed: 29755006

Auteurs

H Abdel-Aty (H)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

K Warren-Oseni (K)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

S Bagherzadeh-Akbari (S)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

V N Hansen (VN)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen, Denmark.

K Jones (K)

Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

V Harris (V)

Department of Radiotherapy, Guy's & St. Thomas' NHS Foundation Trust, London, UK.

M P Tan (MP)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

D Mcquaid (D)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

H A McNair (HA)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

R Huddart (R)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

A Dunlop (A)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

S Hafeez (S)

Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: shaista.hafeez@icr.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Mapping Local Failure Following Bladder...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mapping Local Failure Following Bladder...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Mapping Local Failure Following Bladder...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Dosimétrie en radiothérapie › Mapping Local Failure Following Bladder...
questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Prise de décision assistée par ordinateur › Thérapie assistée par ordinateur › Radiothérapie assistée par ordinateur › Planification de radiothérapie assistée par ordinateur › Mapping Local Failure Following Bladder...
questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Prise de décision assistée par ordinateur › Thérapie assistée par ordinateur › Radiothérapie assistée par ordinateur › Radiothérapie conformationnelle › Radiothérapie conformationnelle avec modulation d'intensité › Mapping Local Failure Following Bladder...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Vessie urinaire › Mapping Local Failure Following Bladder...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › Mapping Local Failure Following Bladder...